Total Payments
$21,450
2024 Payments
$3,460
Companies
90
Transactions
1,097
Medicare Patients
8,724
Medicare Billing
$9.8M
Payment Breakdown by Category
Food & Beverage$21,285 (99.2%)
Education$164.76 (0.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $21,285 | 1,083 | 99.2% |
| Education | $164.76 | 14 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,680 | 77 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,164 | 56 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,091 | 55 | $0 (2024) |
| Amgen Inc. | $1,065 | 47 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,019 | 77 | $0 (2024) |
| PFIZER INC. | $986.95 | 76 | $0 (2024) |
| Janssen Biotech, Inc. | $969.46 | 48 | $0 (2024) |
| Genentech USA, Inc. | $763.27 | 41 | $0 (2024) |
| Lilly USA, LLC | $727.16 | 32 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $708.32 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,460 | 139 | AstraZeneca Pharmaceuticals LP ($319.78) |
| 2023 | $3,497 | 148 | AstraZeneca Pharmaceuticals LP ($397.55) |
| 2022 | $2,902 | 140 | AstraZeneca Pharmaceuticals LP ($248.58) |
| 2021 | $2,152 | 106 | Seagen Inc. ($209.67) |
| 2020 | $681.84 | 34 | Merck Sharp & Dohme Corporation ($71.30) |
| 2019 | $3,028 | 187 | PFIZER INC. ($264.72) |
| 2018 | $2,815 | 178 | Takeda Pharmaceuticals U.S.A., Inc. ($228.21) |
| 2017 | $2,914 | 165 | Amgen Inc. ($368.95) |
All Payment Transactions
1,097 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: Oncology | ||||||
| 12/26/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $21.72 | General |
| 12/24/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 12/21/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Oncology | ||||||
| 12/20/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $29.19 | General |
| Category: Oncology | ||||||
| 12/19/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $34.22 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $26.73 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $44.46 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/11/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $28.24 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Rare Disease | ||||||
| 12/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $31.69 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $33.86 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.47 | General |
| 11/22/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $29.03 | General |
| Category: Hematology/Oncology | ||||||
| 11/12/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $31.00 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.67 | General |
| Category: Hematology | ||||||
| 11/06/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $14.96 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $27.01 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.08 | General |
| Category: Hematology | ||||||
| 10/24/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $33.34 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 44 | 2,231 | 148,043 | $8.4M | $3.5M |
| 2022 | 53 | 2,417 | 157,696 | $7.2M | $2.6M |
| 2021 | 39 | 1,975 | 107,128 | $4.4M | $1.6M |
| 2020 | 43 | 2,101 | 123,041 | $7.2M | $2.1M |
Total Patients
8,724
Total Services
535,908
Medicare Billing
$9.8M
Procedure Codes
179
All Medicare Procedures & Services
179 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 15 | 37,260 | $3.1M | $1.4M | 45.5% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 22 | 32,500 | $3.0M | $1.2M | 41.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 58 | 22,140 | $891,135 | $410,464 | 46.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 150 | 1,081 | $167,610 | $83,359 | 49.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 363 | 790 | $165,115 | $82,157 | 49.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 77 | 646 | $232,560 | $78,919 | 33.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 26 | 497 | $69,580 | $33,621 | 48.3% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 22 | 18,330 | $60,306 | $25,221 | 41.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 107 | 165 | $47,850 | $25,066 | 52.4% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 19 | 22,500 | $50,625 | $19,779 | 39.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 17 | 131 | $58,950 | $17,516 | 29.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 94 | 94 | $32,900 | $16,258 | 49.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 54 | 508 | $43,095 | $13,592 | 31.5% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 32 | 163 | $23,635 | $9,854 | 41.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 193 | 1,181 | $29,525 | $8,987 | 30.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 112 | 591 | $26,550 | $7,276 | 27.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 56 | 117 | $16,380 | $6,855 | 41.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 62 | 445 | $29,055 | $6,270 | 21.6% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 11 | 13 | $16,250 | $5,385 | 33.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 36 | $10,450 | $5,223 | 50.0% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 39 | 265 | $14,575 | $4,802 | 32.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 37 | 170 | $11,050 | $4,410 | 39.9% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 15 | 16 | $7,145 | $3,736 | 52.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 22 | 95 | $8,075 | $2,798 | 34.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 43 | 3,160 | $212,636 | $2,601 | 1.2% |
About Dr. Amy Mcmullen, M.D
Dr. Amy Mcmullen, M.D is a Internal Medicine healthcare provider based in Santa Cruz, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205860954.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amy Mcmullen, M.D has received a total of $21,450 in payments from pharmaceutical and medical device companies, with $3,460 received in 2024. These payments were reported across 1,097 transactions from 90 companies. The most common payment nature is "Food and Beverage" ($21,285).
As a Medicare-enrolled provider, Mcmullen has provided services to 8,724 Medicare beneficiaries, totaling 535,908 services with total Medicare billing of $9.8M. Data is available for 4 years (2020–2023), covering 179 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Santa Cruz, CA
- Active Since 07/10/2006
- Last Updated 07/15/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1205860954
Products in Payments
- KEYTRUDA (Biological) $1,006
- OPDIVO (Biological) $639.16
- ADCETRIS (Biological) $456.49
- TAGRISSO (Drug) $435.98
- VERZENIO (Drug) $411.81
- IMBRUVICA (Drug) $383.69
- Lenvima (Drug) $382.82
- Nplate (Biological) $345.85
- NINLARO (Drug) $333.35
- XTANDI (Drug) $318.41
- JEVTANA (Drug) $314.04
- DARZALEX (Biological) $308.88
- Kyprolis (Biological) $303.88
- JAKAFI (Drug) $289.16
- IMFINZI (Biological) $279.80
- IBRANCE (Drug) $262.99
- Cabometyx (Drug) $262.41
- Lonsurf (Drug) $260.41
- LYNPARZA (Drug) $258.09
- CALQUENCE (Drug) $232.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Santa Cruz
Francisco Rhein
Internal Medicine — Payments: $263,271
Internal Medicine $263,271
Sirish Nakka, Md, MD
Internal Medicine — Payments: $11,714
Internal Medicine $11,714
Daniel Kim, M.d, M.D
Internal Medicine — Payments: $4,710
Internal Medicine $4,710
Dr. Anthony Sturzu, M.d, M.D
Internal Medicine — Payments: $3,445
Internal Medicine $3,445
Scott Drew, D.o, D.O
Internal Medicine — Payments: $3,193
Internal Medicine $3,193
Dr. Tuong Vu, Md, MD
Internal Medicine — Payments: $2,499
Internal Medicine $2,499